期刊文献+

乳腺癌化疗现状及相关研究进展 被引量:27

The Current Situation and Related Progress in the Study of Breast Cancer Chemotherapy
原文传递
导出
摘要 乳腺癌是除非上皮来源肿瘤中女性最常见的恶性肿瘤,在美国平均每3名女性中就有一名患乳腺癌,是女性肿瘤致死中的第二大原因,给政府经济造成了很大的损失。目前,乳腺癌主要是以手术治疗为主,而化疗,放疗等也作为相当重要的辅助治疗应用于临床。这种手术加化疗的治疗方法一直可以取得很好的疗效,甚至于可以保住乳房。近年来,乳腺癌的化疗已逐步成为其治疗的首选方式,包括术后辅助化疗和术前的新辅助化疗。但由于化疗药物的滥用和肿瘤本身的异质性或是其他原因,越来越多的肿瘤耐药性报道给乳腺癌的化疗带来了很大的挑战。而这种肿瘤耐药性的分子机制尚不是很清楚。本文将从乳腺癌的概述,乳腺癌化疗的现状及乳腺癌化疗的前景来综述这一灾难性疾病。 Excluding skin cancers,breast cancer is the most common malignancy among women,accounting for nearly 1 in 3 cancers diagnosed among women in the United States,and it is the second leading cause of cancer death among women;besides,it brings a great financial lost of government.At present,surgery is the main treatment for the disease and chemotherapy or radiotherapy have also become important adjuvant therapies in clinical.This treatment binding surgery and chemotherapy treatments has got a very good curative effect,even can protect from removing the breast.Recent years,chemotherapy has become the preferred way to treat breast cancer,including adjuvant chemotherapy after surgery and neoadjuvant chemotherapy before surgery.However,as the inadaptable ways or other unknown mechanisms,more and more drug resistance have been reported and this brings a great challenge to the therapy of the disease.This review will cover the introduction of breast cancer,the current situation and prospect of this disasters' chemotherapy.
出处 《现代生物医学进展》 CAS 2013年第22期4398-4400,共3页 Progress in Modern Biomedicine
基金 国家自然科学基金项目(30872464)
关键词 乳腺癌 化疗 耐药性 Mammary cancer Chemotherapy Resistance
  • 相关文献

参考文献32

  • 1Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 9 Regs Research Data, Nov. 2010 Sub (1973-2008) <Katrina/Rita Population Adjustment>-Linked to County Attributes-Total US, 1969-2009 Counties. Bethesda,MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; 2011. Released April 2011 based on the November 2010 submission.
  • 2Mc PhersonK, SteelCM, DixonJM. ABC of breast diseases. Breast cancer epidemiology, risk factors, and genetics [J]. BMJ,2000,321(7261):624-628.
  • 3Humphrey, L Chan, BKS.; Detlefsen, S. Screening for breast cancer: systematic evidence review, 2002.
  • 4施冬梅,路永涛,徐哲,于德香.超声检查在乳腺癌诊断中价值的探讨[J].现代生物医学进展,2011,11(4):742-744. 被引量:8
  • 5Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography[J]. CA Cancer J Clin,2007,57(2):75-89.
  • 6Flobbe K, Bosch AM, Kessels AG, et al. The additional diagnostic value of ultrasonography in the diagnosis of breast cancer [J]. Arch Intern Med,2003,163 ( 10): 1194-1199.
  • 7Bedrosian I, Mick R, Orel SG, et al. Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging[J].Cancer, 2003,98(3):468-473.
  • 8Early Breast Cancer Trialist's Collaborative Group [J]. Lancet,1992, 339(1):1-15.
  • 9魏文波,谢祥红,陈纬,张埝,陈玉顺.肿瘤标志物联合检测在乳腺癌早期诊断中的应用[J].现代生物医学进展,2011,11(9):1754-1756. 被引量:13
  • 10Early Breast Cancer Trialist's Collaborative Group [J]. Lancet,1999,3 52:930-947.

二级参考文献51

  • 1景香香,刘望彭,康春松,杨永生,刘利平,袁霞萍,陈武.多普勒超声对乳腺肿块鉴别诊断的研究[J].中国医学影像技术,2003,19(5):552-554. 被引量:40
  • 2娄丽,马玉香,王克,李吉昌,王刚.超声诊断乳腺肿块[J].中国医学影像技术,2004,20(12):1812-1814. 被引量:27
  • 3OmedulIslam,KlausHeese.ABC transporters,neural stem cells and neurogenesis - a different perspective[J].Cell Research,2006,16(11):857-871. 被引量:3
  • 4Chow LWC, Loo WTY. The diferential effects of cyclophosphamide: epirubicinand 5-fluorouracil on apoptotic marker (CPP2 32), pro-apoptotic protein (p21waf21) and anti-apopt'otic protein (bel-2) in breast cancer cells [J]. Breast Cancer Res Treat , 2003 , 80 (3): 239-244.
  • 5M.E. Valk-Lingbeek, S.W. Bruggeman, M. van Lohuizen, Stem cells and cancer; the polycomb connection[J]. Cell. 2004, 118 (4): 409-18.
  • 6Y. Haupt, W.S. Alexander, G. Barri, et al. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice[J]. Cell, 1991, 65(5): 753-63.
  • 7M. van Lohuizen, S. Verbeek, B. Scheijen, et al. Identification of coop- erating oncogenes in E mu-myc transgenic mice by provirus tagging [J]. Cell, 1991, 65 : 737-52.
  • 8Fischle W, Wang Y, Jacobs SA, et al. Molecular basis for the discrimination of repressive methyl-lysine marks in histone H3 by Polycomb and HP 1 chromodomains[J]. Genes Dev, 2003, 17(15): 1870-81.
  • 9Vrzalikova K, Skarda J, Ehrmann J, et al. Prognostic value of BMI-1 oncoprotein expression in NSCLC patients: a tissue microarray study [J]. J Cancer Res Clin Oncol, 2008, 134(9): 1037-42.
  • 10Godlewski J, Nowicki MO, Bronisz A, et al. Targeting of the BMI-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal[J]. Cancer Res, 2008, 68(22): 9125-30.

共引文献45

同被引文献222

引证文献27

二级引证文献148

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部